DiaMedica Therapeutics Q3 EPS $(0.12) Beats $(0.13) Estimate
Portfolio Pulse from Benzinga Newsdesk
DiaMedica Therapeutics reported Q3 EPS of $(0.12), surpassing the consensus estimate of $(0.13) by 7.69%. The EPS figure remains the same as the previous year's same quarter.
November 13, 2023 | 9:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DiaMedica Therapeutics reported a smaller-than-expected quarterly loss, beating estimates by 7.69% with an EPS of $(0.12), which is consistent with the prior year's performance.
Beating EPS estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. The match with last year's performance indicates stability, which can also be viewed positively by the market.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100